Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yin, Hongmei ^a,b   Chen, Naifei ^a,b   Guo, Rui ^a,b   Wang, Hong ^a,b   Li, Wei ^a   Wang, Guanjun ^a   Cui, Jiuwei ^a   Jin, Haofan ^a   Hu, Ji Fan ^a,b  

^a JILIN UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; GEMCITABINE; HYBRID PROTEIN; PEPTIDE; PGF PROTEIN, HUMAN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; STAT1 PROTEIN;

ANALOGS AND DERIVATIVES; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR MODEL; PANCREAS TUMOR; PATHOLOGY; PROTEIN CONFORMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INTERFERON-ALPHA; MODELS, MOLECULAR; PANCREATIC NEOPLASMS; PEPTIDES; PLACENTA GROWTH FACTOR; PREGNANCY PROTEINS; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84947711188     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16975     Document Type: Article

References (56)

1. Siegel, R., Ward, E., Brawley, O., Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212-236 (2011).
2. Jemal, A., Siegel, R., Xu, J., Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277-300 (2010).
3. Hidalgo, M. Pancreatic cancer. N Engl J Med 362, 1605-1617 (2010).
4. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364, 1817-1825 (2011).
5. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691-1703 (2013).
6. Clavien, P. A. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection Ann Surg 245, 843-845 (2007).
7. Lo, C. M. et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245, 831-842 (2007).
8. Hoffmann, K., Mehrle, S., Schmidt, J., Buchler, M. W., Marten, A. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res 28, 1499-1507 (2008).
9. Sleijfer, S., Bannink, M., Van Gool, A. R., Kruit, W. H., Stoter, G. Side effects of interferon-alpha therapy. Pharm World Sci 27, 423-431 (2005).
10. Jonasch, E., Haluska, F. G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34-55 (2001).
11. Martino, M. M. et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 343, 885-888 (2014).
12. Mazur, P.K. et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283-283 (2014).
13. Zhang, H. et al. Intrachromosomal Looping Is Required for Activation of Endogenous Pluripotency Genes during Reprogramming. Cell Stem Cell 13, 30-35 (2013).
14. Zhang, H. et al. Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. J Cell Biol 204, 61-75 (2014).
15. Zhang, H. et al. Interruption of intrachromosomal looping by CTCF decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. J Cell Biol 193, 475-487 (2011).
16. Ma, A. N. et al. Targeted gene suppression by inducing de novo DNA methylation in the gene promoter. Epigenetics Chromatin 7, 20 (2014).
17. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat Methods 12, 7-8 (2015).
18. Roy, A., Kucukural, A., Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5, 725-738 (2010).
19. Wang, H. et al. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies. Int J Cancer 135, 2783-2794 (2014).
20. Zhang, S. et al. Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int J Cancer 134, 1583-1594 (2014).
21. Li, T. et al. CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex-2 intrachromosomal loop. Mol Cell Biol 28, 6473-6482 (2008).
22. Sun, J. et al. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res 42, 9588-9601 (2014).
23. Novak, A. J. et al. A role for IFN-lambda1 in multiple myeloma B cell growth. Leukemia 22, 2240-2246 (2008).
24. Xue, Q., Yang, L., Liu, X., Liu, W. Molecular characterization of feline type I interferon receptor 2. J Interferon Cytokine Res 30, 81-88 (2010).
25. Li, T. et al. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet 23, 117-128 (2014).
26. Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6, 975-990 (2007).
27. Schoenborn, J. R., Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96, 41-101 (2007).
28. Bach, E. A., Aguet, M., Schreiber, R. D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15, 563-591 (1997).
29. Pestka, S., Langer, J. A., Zoon, K. C., Samuel, C. E. Interferons and their actions. Annu Rev Biochem 56, 727-777 (1987).
30. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., Schreiber, R. D. How cells respond to interferons. Annu Rev Biochem 67, 227-264 (1998).
31. Takaoka, A., Yanai, H. Interferon signalling network in innate defence. Cell Microbiol 8, 907-922 (2006).
32. Blouin, C. M., Lamaze, C. Interferon gamma receptor: the beginning of the journey. Front Immunol 4, 267 (2013).
33. Copolovici, D. M., Langel, K., Eriste, E., Langel, U. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8, 1972-1994 (2014).
34. Trabulo, S. et al. Cell-penetrating peptides as nucleic acid delivery systems: from biophysics to biological applications. Curr Pharm Des 19, 2895-2923 (2013).
35. Deshayes, S., Morris, M. C., Divita, G., Heitz, F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 62, 1839-1849 (2005).
36. Green, M., Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179-1188 (1988).
37. Morris, M. C., Vidal, P., Chaloin, L., Heitz, F., Divita, G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25, 2730-2736 (1997).
38. Dilber, M. S. et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 6, 12-21 (1999).
39. Choi, Y. S., David, A. E. Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol 15, 192-199 (2014).
40. Farkhani, S. M. et al. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides 57, 78-94 (2014).
41. Madani, F., Lindberg, S., Langel, U., Futaki, S., Graslund, A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011, 414729 (2011).
42. Schultz, G. S., Davidson, J. M., Kirsner, R. S., Bornstein, P., Herman, I. M. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 19, 134-148 (2011).
43. Lortat-Jacob, H., Esterre, P., Grimaud, J. A. Interferon-gamma, an anti-fibrogenic cytokine which binds to heparan sulfate. Pathol Res Pract 190, 920-922 (1994).
44. Sangfelt, O. et al. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 8, 343-352 (1997).
45. Luchetti, F. et al. The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha. Haematologica 83, 974-980 (1998).
46. Dai, C., Krantz, S. B. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 93, 3309-3316 (1999).
47. Booy, S., Hofland, L., van Eijck, C. Potentials of interferon therapy in the treatment of pancreatic cancer. J Interferon Cytokine Res 35, 327-339 (2015).
48. Thyrell, L. et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 21, 1251-1262 (2002).
49. Barton, C., Davies, D., Balkwill, F., Burke, F. Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer 41, 1474-1486 (2005).
50. Tailor, P. et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 27, 228-239 (2007).
51. Mancuso, G. et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 10, 587-594 (2009).
52. Trinchieri, G. Type I interferon: friend or foe J Exp Med 207, 2053-2063 (2010).
53. Maeda, S. et al. Interferon-alpha acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem 289, 23786-23795 (2014).
54. Sangfelt, O. et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18, 2798-2810 (1999).
55. Grebenova, D. et al. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol Dis 32, 262-269 (2004).
56. Tiefenbrun, N. et al. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 16, 3934-3944 (1996).